Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Targeting HER2-AXL heterodimerization to overcome resistance to HER2 blockade in breast cancer
Anna Adam‐Artigues, Enrique J. Arenas, Alex Martínez-Sabadell, et al.
Science Advances (2022) Vol. 8, Iss. 20
Open Access | Times Cited: 40

Showing 1-25 of 40 citing articles:

Encapsulation of Tetraphenylethylene Derivative in Liposome Vesicles as Promising Aggregation-Induced Electrochemiluminescence Emitter for Detection of Human Epidermal Growth Factor Receptor 2
Yue Jia, Xiang Ren, Xiaoyue Zhang, et al.
Analytical Chemistry (2023) Vol. 95, Iss. 24, pp. 9139-9144
Closed Access | Times Cited: 73
AXL in cancer: a modulator of drug resistance and therapeutic target
Yaoxiang Tang, Hongjing Zang, Qiuyuan Wen, et al.
Journal of Experimental & Clinical Cancer Research (2023) Vol. 42, Iss. 1
Open Access | Times Cited: 47
TAM family kinases as therapeutic targets at the interface of cancer and immunity
Deborah DeRyckere, Justus M. Huelse, H. Shelton Earp, et al.
Nature Reviews Clinical Oncology (2023) Vol. 20, Iss. 11, pp. 755-779
Closed Access | Times Cited: 46
A Multifunctional Bimetallic Nanoplatform for Synergic Local Hyperthermia and Chemotherapy Targeting HER2‐Positive Breast Cancer
Li Zhao, Fei Chang, Yao Tong, et al.
Advanced Science (2024) Vol. 11, Iss. 16
Open Access | Times Cited: 16
AXL signaling in cancer: from molecular insights to targeted therapies
Monika Yadav, Anuj K. Sharma, Ketki Patne, et al.
Signal Transduction and Targeted Therapy (2025) Vol. 10, Iss. 1
Open Access | Times Cited: 3
AXL: shapers of tumor progression and immunosuppressive microenvironments
Yihui Liu, Lei Xu, Yuanyao Dou, et al.
Molecular Cancer (2025) Vol. 24, Iss. 1
Open Access | Times Cited: 2
HER2-Positive Breast Cancer Treatment and Resistance
Jamunarani Veeraraghavan, Carmine De Angelis, Carolina Gutiérrez, et al.
Advances in experimental medicine and biology (2025), pp. 495-525
Closed Access | Times Cited: 2
Clinical Impact of New Treatment Strategies for HER2-Positive Metastatic Breast Cancer Patients with Resistance to Classical Anti-HER Therapies
Marta Tapia, Cristina Hernándo, María Teresa Martínez, et al.
Cancers (2023) Vol. 15, Iss. 18, pp. 4522-4522
Open Access | Times Cited: 20
AXL/WRNIP1 Mediates Replication Stress Response and Promotes Therapy Resistance and Metachronous Metastasis in HER2+ Breast Cancer
Mauricio Marquez-Palencia, L Herrera, Pravat Kumar Parida, et al.
Cancer Research (2024) Vol. 84, Iss. 5, pp. 675-687
Open Access | Times Cited: 8
Discovery of AXL Degraders with Improved Potencies in Triple-Negative Breast Cancer (TNBC) Cells
Rui He, Zhiqiang Song, Yu Bai, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 3, pp. 1873-1891
Closed Access | Times Cited: 15
Therapeutic Landscape of AXL Receptor Kinase in Triple-Negative Breast Cancer
Rumeysa Özyurt, Bülent Özpolat
Molecular Cancer Therapeutics (2023) Vol. 22, Iss. 7, pp. 818-832
Closed Access | Times Cited: 13
Emerging insights into mechanisms of trastuzumab resistance in HER2-positive cancers
Xiaoxue Wu, Shuting Huang, Weiling He, et al.
International Immunopharmacology (2023) Vol. 122, pp. 110602-110602
Closed Access | Times Cited: 11
Exosomal microRNA as a key regulator of PI3K/AKT pathways in human tumors
Saade Abdalkareem Jasim, Abdulrahman T. Ahmed, Aziz Kubaev, et al.
Medical Oncology (2024) Vol. 41, Iss. 11
Closed Access | Times Cited: 4
The Biological Roles and Clinical Applications of the PI3K/AKT Pathway in Targeted Therapy Resistance in HER2-Positive Breast Cancer: A Comprehensive Review
Hanyi Zhong, Ziling Zhou, Han Wang, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 24, pp. 13376-13376
Open Access | Times Cited: 4
AXL-SHC1 Signaling Axis Mediates Intrinsic Resistance to HER2-Targeted Tyrosine Kinase Inhibitors in HER2-Aberrant Lung and Gastric Cancers
Masaki Ishida, Tadaaki Yamada, Yuki Katayama, et al.
(2025)
Closed Access
Navigating TAM receptor dynamics in tumour immunotherapy
Jihao Yang, Guanmin Chen, Rui Wang, et al.
Cancer Immunology Immunotherapy (2025) Vol. 74, Iss. 5
Open Access
Alkaline phosphatase-responsive peptide amphiphiles promote the apoptosis of HER2-positive breast cancer cells via increased drug accumulation
Aimei Li, Tian Xue, Feihu Hu, et al.
Colloids and Surfaces A Physicochemical and Engineering Aspects (2025), pp. 136848-136848
Closed Access
A Receptor Tyrosine Kinase Inhibitor Sensitivity Prediction Model Identifies AXL Dependency in Leukemia
Ahmad Nasimian, Lina Al Ashiri, Mehreen Ahmed, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 4, pp. 3830-3830
Open Access | Times Cited: 10
A bibliometric and visualization analysis of research trends and hotspots on targeted therapy for breast cancer from 2003 to 2022
Deqi Wu, Pan Chi, Yangying Hu, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 3
The Role of Tumor-Associated Antigen HER2/neu in Tumor Development and the Different Approaches for Using It in Treatment: Many Choices and Future Directions
Saleh Alrhmoun, С. В. Сенников
Cancers (2022) Vol. 14, Iss. 24, pp. 6173-6173
Open Access | Times Cited: 15
Discovery of novel and potent dual-targeting AXL/HDAC2 inhibitors for colorectal cancer treatment via structure-based pharmacophore modelling, virtual screening, and molecular docking, molecular dynamics simulation studies, and biological evaluation
Qiao Xiao, Xiangyu Wu, Shutong Chen, et al.
Journal of Enzyme Inhibition and Medicinal Chemistry (2023) Vol. 39, Iss. 1
Open Access | Times Cited: 9
AXL – a new player in resistance to HER2 blockade
Anna Adam‐Artigues, Enrique J. Arenas, Joaquı́n Arribas, et al.
Cancer Treatment Reviews (2023) Vol. 121, pp. 102639-102639
Open Access | Times Cited: 8
Progress of PD-1/PD-L1 inhibitor combination therapy in immune treatment for HER2-positive tumors
Sining Zhao, Yiwu Qiu, Meiqin Yuan, et al.
European Journal of Clinical Pharmacology (2024) Vol. 80, Iss. 5, pp. 625-638
Closed Access | Times Cited: 2
Preparation of an Ultrahigh-DAR PDL1 monoclonal antibody-polymeric-SN38 conjugate for precise colon cancer therapy
Honglei Zhang, Jiali Sun, Yu Zhang, et al.
Biomaterials (2023) Vol. 301, pp. 122285-122285
Closed Access | Times Cited: 5
First evidence of AXL expression on circulating tumor cells in metastatic breast cancer patients: A proof‐of‐concept study
Thomas Bardol, Zahra Eslami‐S, Doryan Masmoudi, et al.
Cancer Medicine (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 5
Page 1 - Next Page

Scroll to top